LXN and prostate cancer: In order to understand the wider relevance of this finding, we interrogated a publicly available dataset (Grasso et al. 2012) and found LXN mRNA levels to be significantly downregulated in metastatic prostate cancer specimens when compared to normal prostate tissue (Fig. 1G)23,24.